Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - neisseria meningitidis a+c+w+y, purified polysaccharides - powder and solvent for solution for injection - neisseria meningitidis a+c+w+y, purified polysaccharides - meningococcus a,c,y,w-135, tetravalent purified polysaccharides antigen

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

nuron biotech b.v. - neisseria meningitidis group c oligosaccharide conjugated to crm197 as a carrier - suspension for injection in pre-filled syringe - 10 µg - neisseria meningitidis c, oligosaccharide conjugated to crm 197 as a carrier - meningococcus c, purified polysaccharides antigen conjugated

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gsk vaccines s.r.l. - neisseria meningitidis group c oligosaccharide conjugated to crm197 as a carrier 10 µg - suspension for injection - 10 µg - neisseria meningitidis c, oligosaccharide conjugated to crm 197 as a carrier - meningococcus c, purified polysaccharides antigen conjugated

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gsk vaccines s.r.l. - neisseria meningitidis group c oligosaccharide conjugated to crm197 as a carrier 10 µg - suspension for injection in pre-filled syringe - 10 µg - neisseria meningitidis c, oligosaccharide conjugated to crm 197 as a carrier - meningococcus c, purified polysaccharides antigen conjugated

Panama - englanti - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

pfizer europe ma eeig - neisseria meningitidis serogrupo b fhbp subfamilia a - neisseria meningitidis serogrupo b fhbp subfamilia a....60 mcg. / neisseria meningitidis serogrupo b fhbp subfamilia b....60 mcg.

Yhdysvallat - englanti - NLM (National Library of Medicine)

msp vaccine company - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - vaxelis® is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, inclu

Filippiinit - englanti - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: zuellig pharma corporation - meningococcal group a, c, w-135 and y conjugate vaccine - solution for injection (im) - formulation: each dose (0.5 ml) contains: neisseria meningitidis group a polysaccharide* .... 10 mcg neisseria meningitidis group c polysaccharide* .... 10 mcg neisseria meningitidis group y polysaccharide* .... 10 mcg neisseria meningitidis group w-135 polysaccharide* .... 10 mcg *conjugated to tetanus toxoid carrier protein... 55 mcg** **tetanus toxoid quantity is approximate and dependent on the polysaccharide to protein ratio for the conjugates in each formulation

Yhdysvallat - englanti - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conj - penbraya is indicated for active immunization to prevent invasive disease caused by neisseria meningitidis serogroups a, b, c, w, and y. penbraya is approved for use in individuals 10 through 25 years of age. do not administer penbraya to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of penbraya [see description (11)] .              pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to penbraya during pregnancy. individuals who received penbraya during pregnancy are encouraged to contact, or have their healthcare provider contact, 1-877-390-2953 to enroll in or obtain information about the registry. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no clinical studi

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - neisseria meningitides,group w-135 polysaccaride; neisseria meningitides,group c polysaccharide; neisseria meningitides,group a polysaccharide; neisseria meningitides,group y polysaccharide -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group a polysaccharide 100 µg/ml; neisseria meningitidis group c polysaccharide 100 µg/ml - powder for injection - 50µg,50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 100 µg/ml neisseria meningitidis group c polysaccharide 100 µg/ml excipient: lactose monohydrate